Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Levulan Kerastick in Actinic Keratosis
NCT02281136Phase 2Completed
- Sponsor
- DUSA Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK), sponsored by DUSA Pharmaceuticals. Primary endpoints: Maximum Baseline Corrected Plasma Concentration at 1 day, Time at Which Cmax is Attained at 1 day and 2 more. Started Dec 2014; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02281136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281136.